For the year ending 2025-12-31, TNXP had $110,127K increase in cash & cash equivalents over the period. -$103,213K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -124,021 |
| Depreciation and amortization | 1,925 |
| Bad debt expense | 31 |
| Stock-based compensation | 6,017 |
| Loss on extinguishment of debt | -2,092 |
| Loss on note | -1,159 |
| Inventory write-off | 669 |
| Amortization of debt discounts | 65 |
| Issuance costs of derivative instrument | 1,837 |
| Accounts receivable | 2,619 |
| Inventory | -1,726 |
| Prepaid expenses and other | 3,161 |
| Accounts payable | 2,994 |
| Operating lease liabilities and rou asset, net | -303 |
| Accrued expenses and other current liabilities | 11,745 |
| Net cash used in operating activities | -99,844 |
| Issuance of note | 2,012 |
| Proceeds from note | 853 |
| Purchase of property and equipment | 3,369 |
| Net cash used in investing activities | -4,528 |
| Repayments of term loan | 9,650 |
| Proceeds, net of 8,750 and 7,238 expenses, from sale of common stock and warrants, respectively | 237,940 |
| Repurchase of common stock, net of 30 expenses | 13,760 |
| Net cash provided by financing activities | 214,530 |
| Effect of currency rate change on cash | -31 |
| Net increase in cash, cash equivalents and restricted cash | 110,127 |
| Cash, cash equivalents and restricted cash beginning of the period | 99,680 |
| Cash, cash equivalents and restricted cash end of period | 209,807 |
Tonix Pharmaceuticals Holding Corp. (TNXP)
Tonix Pharmaceuticals Holding Corp. (TNXP)